UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 12b-25


NOTIFICATION OF LATE FILING



Commission File Number:   333-201719

  

  

  

(Check One):

o  Form 10-K

o  Form 20-F

¨  Form 11-K

þ  Form 10-Q

¨  Form 10-D

  

  

  

o  Form N-SAR

o  Form N-CSR

  

  

  

For Period Ended:

September 30, 2016

  

  

 

¨    Transition Report on Form 10-K

o   Transition Report on Form 20-F

o   Transition Report on Form 11-K

o   Transition Report on Form 10-Q

o   Transition Report on Form N-SAR

  

  

For the Transition Period Ended:

 

  

  

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

BIOTRICITY INC.


Full Name of Registrant

 


Former Name if Applicable

 

275 Shoreline Drive, Suite 150

Address of Principal Executive Office (Street and Number)

 

Redwood City, California 94065

City, State and Zip Code

 

  

 



 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

þ

  

  

  

  

  

  

  

(a)

  

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

  

  

  

  

  

  

  

(b)

  

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

  

  

  

  

  

  

  

  

(c)

  

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


The Form 10-Q for the fiscal quarter ended September 30, 2016 will not be submitted by the deadline without unreasonable effort or expense. The Registrant had unanticipated delays in the collection and compilation of certain information required to be included in the Form 10-Q. The Registrant will file the Form 10-Q on or before the fifth calendar day following the prescribed due date.

 

(Attach extra Sheets if Needed)



PART IV — OTHER INFORMATION

 

(1)

  

Name and telephone number of person to contact in regard to this notification


Waqaas Al-Siddiq

  

416

  

214-3678

(Name)

  

(Area Code)

  

(Telephone Number)


(2)

  

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

  

  

Yes  þ      No  o


(3)

  

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

  

  

Yes  þ      No o  

  

  

  

  

  

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 The results of operations of the registrant for the fiscal quarter ended September 30, 2016 has significant changes from the results of operations of the registrant from the corresponding period of the last fiscal year as a result of the assignment of its then-existing assets, liabilities and operations and concurrent acquisition on February 2, 2016 of the business and operations of iMedical Innovations, Inc.


  



 

Biotricity Inc.


(Name of Registrant as Specified in Charter)

 

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

  

  

  

  

  

  

  

Date

  

November 14, 2016

  

By

  

/s/   WAQAAS AL-SIDDIQ      

  

  

  

  

  

  

Waqaas Al-Siddiq, CEO